Cardiometabolic conditions could be related to vitamin D deficiency. The genetic determinants that affect vitamin D pathways may be solved with nanomedicines.

Vitamin D deficiency is a risk factor for cardiometabolic disorders.Nanomedicines can be used to treat atherosclerosis and associated ischemicdisorders. They are able to reduce internal clearance pathways and prolongblood circulation. They also have a large surface size and more sensitive andvaried reactivity than bulk materials, making them more effective at targetingand functionalizing nanoparticles for various types of disease. This studyfocuses on the specialized use of nanomedicine for atherosclerotic diseases inpreclinical and clinical practice. It presents the most recent developments innanomedicine-based treatment regimens for the disease. It has the potential tosolve the genetic determinants that influence vitamin D pathways.